| Issue Date | Title | Author(s) |
| 14-Sep-2024 | Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial | Yang, Shenmiao; Huang, Haiwen; Zhou, Keshu; Zhao, Xielan; Han, Yanqiu; Li, Lindong; Wang, Yujie; Liu, Xiaofeng; Li, Jianyong |
| Jun-2021 | Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study | Dou, Xuelin; Zheng, Fangyuan; Zhang, Liqiang; Jin, Jie; Zhang, Yanli; Liu, Bingcheng; Meng, Li; Zhu, Xiaofan; Lu, Zesheng; Jia, Yueping; Liu, Huilan; Lin, Hai; Zhou, Li; Zhao, Xielan; Yang, Wei; Sun, Hui; Qian, Sixuan; Ma, Hongxia; Du, Xin; Bai, Qingxian; Xu, Na; Meng, Fanjun; Jia, Zhilin; Di, Haixia; Zhang, Leping; Jiang, Qian |
| 2017 | Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis: A non-comparative, multicenter, phase IV, open-label study | Ji, Yu; Song, Yongping; Zhou, Fang; Liu, Ting; Jiang, Ming; Zhao, Xielan; Huang, Xiaojun |
| 15-Jul-2020 | Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20(+) B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study | Jiang, Bo; Ke, Xiaoyan; Zhang, Qingyuan; Xu, Wei; Su, Hang; Huang, Jie; Zhang, Mingzhi; Wang, Huaqing; Jin, Chuan; Zhu, Jun; Liu, Li; Cai, Zhen; Zhao, Xielan; Zhou, Jianfeng; Zhang, Xiaohong; Liu, Jing; Zhou, Hui; Yu, Jie; Sun, Xing; Qi, Junyuan; Qiu, Lugui |
| 16-Apr-2020 | A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma | Shi, Yuankai; Song, Yongping; Qin, Yan; Zhang, Qingyuan; Han, Xiaohong; Hong, Xiaonan; Wang, Dong; Li, Wei; Zhang, Yang; Feng, Jifeng; Yang, Jianmin; Zhang, Huilai; Jin, Chuan; Yang, Yu; Hu, Jianda; Wang, Zhao; Jin, Zhengming; Su, Hang; Wang, Huaqing; Yang, Haiyan; Fu, Weijun; Zhang, Mingzhi; Zhang, Xiaohong; Chen, Yun; Ke, Xiaoyan; Liu, Li; Yu, Ding; Chen, Guo'an; Wang, Xiuli; Jin, Jie; Sun, Tao; Du, Xin; Cheng, Ying; Yi, Pingyong; Zhao, Xielan; Ma, Chaoming; Cheng, Jiancheng; Chai, Katherine; Luk, Alvin; Liu, Eugene; Zhang, Xin |
| 2015 | Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma | Shi, Yuankai; Dong, Mei; Zhu, Jun; Zhou, Daobin; Huang, Huiqiang; Tu, Ping; Zhang, Weijing; Hong, Xiaonan; Zhao, Xielan; Sun, Jianfang; Liu, Yuehua; Qiu, Lugui; Shen, ZhiXiang; Feng, Jifeng; Ke, Xiaoyan |
| 2015 | Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma | Shi, Yuankai; Dong, Mei; Zhu, Jun; Zhou, Daobin; Huang, Huiqiang; Tu, Ping; Zhang, Weijing; Hong, Xiaonan; Zhao, Xielan; Sun, Jianfang; Liu, Yuehua; Qiu, Lugui; Shen, ZhiXiang; Feng, Jifeng; Ke, Xiaoyan |
| 2015 | Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL) | Wang, Jianxiang; Mi, Yingchang; Jiang, Bin; Chen, Xiequn; Ji, Chunyan; Li, Yan; Zhao, Xielan; Lai, Yongrong; Hu, Yu; Tang, Aiping; Liu, Ting; Jin, Jie; Li, Junmin; Yang, Linhua; Li, Jinyong; Meng, Fanyi |
| 2015 | Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL) | Wang, Jianxiang; Mi, Yingchang; Jiang, Bin; Chen, Xiequn; Ji, Chunyan; Li, Yan; Zhao, Xielan; Lai, Yongrong; Hu, Yu; Tang, Aiping; Liu, Ting; Jin, Jie; Li, Junmin; Yang, Linhua; Li, Jinyong; Meng, Fanyi |
